
Browsing restrictions can be lifted for a fee.
-2.82%
Lucid diagnostics inc.
0.05%
Avg of Sector
-0.31%
S&P500

Browsing restrictions can be lifted for a fee.
| Quarterly | EPS Forecast | QoQ | Max | Min |
|---|---|---|---|---|
| 2026Q1 | ||||
| 2026Q2 | ||||
| 2026Q3 | ||||
| 2026Q4 | ||||
| 2027Q1 |
Lucid Diagnostics Inc. operates as a commercial-stage medical diagnostics technology company. The company focuses on patients with gastroesophageal reflux disease, which is also known as chronic heartburn, acid reflux, or simply reflux, who are at risk of developing esophageal precancer and cancer, specifically highly lethal esophageal adenocarcinoma. Its lead products include EsoGuard, a laboratory developed esophageal DNA test; and EsoCheck, an esophageal cell collection device. The company was incorporated in 2018 and is based in New York, New York. Lucid Diagnostics Inc. is a subsidiary of PAVmed Inc.
Unit : USD
| QTR | Non-GAAP EPS | EPS YoY | EPS Surprise % | Sales | Sales YoY | Sales Surprise % | NPM |
|---|---|---|---|---|---|---|---|
| Current | |||||||
| 2025Q4 | |||||||
| 2025Q3 | |||||||
| 2025Q2 | |||||||
| 2025Q1 |
The most recent financial report for Lucid diagnostics inc. (LUCD) covers the period of 2025Q3 and was published on 2025/09/30. This report is prepared according to IFRS/US GAAP standards and includes key financial indicators—Revenue, Profitability, Cash Flow, and Capital Structure. This information is essential for investors evaluating LUCD's short-term business performance and financial health. For the latest updates on LUCD's earnings releases, visit this page regularly.
According to the latest financial report, Lucid diagnostics inc. (LUCD) reported an Operating Profit of -11.76M with an Operating Margin of -971.02% this period, representing a decline of 0.56% compared to the same period last year. Operating Profit reflects the company's core business efficiency and cost control, making it a key indicator for evaluating operational strength and profitability.
In the latest financial report, Lucid diagnostics inc. (LUCD) announced revenue of 1.21M, with a Year-Over-Year growth rate of 3.33%. Revenue growth can be driven by product mix changes, market share expansion, price adjustments, or international market penetration. Investors should also monitor gross margin and regional revenue distribution for a comprehensive view of growth quality and sustainability.
As of the end of the reporting period, Lucid diagnostics inc. (LUCD) had total debt of 24.34M, with a debt ratio of 0.46. Short-term debt comprises a higher/lower proportion. The level of financial leverage directly impacts the company's capital structure and interest coverage. If debt is high, pay attention to interest expenses and refinancing risks. Conversely, a low-leverage structure indicates greater risk tolerance but potentially less growth flexibility.
At the end of the period, Lucid diagnostics inc. (LUCD) held Total Cash and Cash Equivalents of 47.33M, accounting for 0.89 of total assets. Both current and quick ratios indicate robust short-term debt repayment ability. High cash reserves typically mean the company has strong liquidity, supporting operational needs, expansion investments, or shareholder returns.
In the latest report, Lucid diagnostics inc. (LUCD) did not achieve the “three margins increasing” benchmark, with a gross margin of -40.1%%, operating margin of -971.02%%, and net margin of -858.5%%. This demonstrates limited improvement in profitability, which is a key signal for fundamental analysis. Investors should consider margin trends alongside other financial indicators to assess LUCD's profit trajectory and future growth potential.
According to the past four quarterly reports, Lucid diagnostics inc. (LUCD)'s earnings per share (EPS) shows a steady growth trend, with the latest EPS at -0.1. If EPS continues to rise due to revenue growth and cost optimization, it can support P/E valuation recovery and attract long-term investors.
Lucid diagnostics inc. (LUCD)'s Free Cash Flow (FCF) for the period is -10.92M, calculated as Operating Cash Flow minus Capital Expenditures, representing a fall of 7.33% compared with the previous period. Positive FCF growth provides stable funding for dividends, debt repayment, or strategic acquisitions, and is an important measure of true profitability and shareholder return potential.